Adriana Funderáková Beňová
PharmDr. Adriána Funderáková Beňová is a pharmaceutical executive with over 18 years of experience. She currently serves as Head of Public Affairs at Bayer, where she develops impactful strategies to enhance Bayer’s reputation and operational flexibility across Czech, Slovakia, Slovenia, and Croatia. Her efforts align with the company’s global priorities and mission: "Health for All, Hunger for None." Adriana joined Bayer in 2006 as a Brand Manager and quickly advanced through various executive positions, including a role at the headquarters in Berlin. As the Country Divisional Head for Pharmaceuticals in the Czech Republic and Slovakia, she drove significant market growth and improved Bayer's strategic positioning in these markets. In her role as Market Access Chapter Head for Central Eastern European Countries, Adriana managed market access strategies across Poland, Czech Republic, Slovakia, and Hungary. She tackled complex market access issues to improve product availability for patients and aligned Bayer’s offerings with regional healthcare needs. Before Bayer, Adriana held several key positions at Sanofi and Sevier, adding to her extensive industry experience. She earned her Doctorate in Pharmacy from Univerzita Komenského v Bratislave, combining deep industry knowledge with an understanding of practical aspects of market dynamics to enhance stakeholder engagement She is an active advocate of fostering cooperation between future generations of scientists and the industry (she coauthored a cooperation between Comenius University and Bayer) and speaker at various industry forums.
Sign in to ITAPA AI 2025
-
The role of European legislation in investment in innovation (10 min)
Europe has the potential to become a leader in the research and development of new medicines, but geopolitical changes require a rethink of healthcare approaches. Policymakers have a choice: continue in the same vein, caring for an increasing number of people. At the same time, budgets stagnate or even decline, or rethink how healthcare is organized and how budgets are allocated. This means taking a more strategic approach to investments that will improve patient health, strengthen healthcare sustainability, and deliver long-term economic growth and security. Adequate intellectual property protection is key to the sustainability of drug development and investment in the EU. The proposed legislative changes in this area may weaken the innovative pharmaceutical industry and widen the gap in competitiveness and availability of medicines, including in Slovakia. It is essential to thoroughly assess these changes and their impact on the healthcare sector.